Korea's Hanmi names triple-agonist candidate zantrutide and launches Eppe at about half Mounjaro's price
The WHO has given Hanmi's GLP-1/GIP/glucagon candidate HM15275 the name zantrutide, which is not an approval. Separately, Hanmi's once-weekly efpeglenatide jab Eppe, Korea's first home-grown GLP-1 for obesity, reaches clinics on 29 October at about 130,000 won for the first month versus about 270,000 won for Mounjaro's lowest dose.
Source: Aju Press (25 Oct 2026).